Apellis Pharmaceuticals, Inc. (APLS)
SEC fundamentals · as filed in 10-Q FY2026, period ended Mar 31, 2026 · updated Oct 6, 2026
as filed in 10-Q FY2026, period ended Mar 31, 2026 · View filings on EDGAR ↗
In its 10-Q for the period ended Mar 31, 2026, Apellis Pharmaceuticals, Inc. reported revenue of $268.3M, net income of $18.7M, and total assets of $1.08B. Every figure below is taken directly from Apellis Pharmaceuticals, Inc.'s SEC filings: each links to the source document on EDGAR.
Revenue trend
Revenue · FY2020–FY2025 · as reported
- FY2020 revenue
- $250.6M
- FY2025 revenue
- $1.00B
Revenue and net income by fiscal year
As reported in each year’s annual filing · USD
| Fiscal year | Revenue | Net income |
|---|---|---|
| FY2025 | $1.00B | $22.4M |
| FY2024 | $781.4M | -$197.9M |
| FY2023 | $396.6M | -$528.6M |
| FY2022 | $75.4M | -$652.2M |
| FY2021 | $66.6M | -$746.4M |
| FY2020 | $250.6M | -$344.9M |
| FY2019 | — | -$304.7M |
| FY2018 | — | -$127.5M |
| FY2017 | — | -$51.0M |
| FY2016 | — | -$27.1M |
Recent SEC filings
Filed by the registrant · newest first · insider forms and holder schedules not included
| Form | Filed | Source |
|---|---|---|
| 8-K | May 14, 2026 | on EDGAR ↗ |
| 10-Q | May 7, 2026 | on EDGAR ↗ |
| 8-K | May 4, 2026 | on EDGAR ↗ |
| 10-K/A | Apr 28, 2026 | on EDGAR ↗ |
| 8-K | Mar 31, 2026 | on EDGAR ↗ |
| 8-K | Mar 2, 2026 | on EDGAR ↗ |
| 10-K | Feb 24, 2026 | on EDGAR ↗ |
| 8-K | Jan 12, 2026 | on EDGAR ↗ |
| 10-Q | Oct 30, 2025 | on EDGAR ↗ |
| 10-Q | Jul 31, 2025 | on EDGAR ↗ |
Balance Sheet
as of Mar 31, 2026 · 10-Q
Income Statement
10-Q (quarterly) · period ended Mar 31, 2026
Per Share & Cash Flow
10-Q (quarterly) · period ended Mar 31, 2026
| EPS (diluted) | $0.15 | Earnings | source ↗ |
| EPS (basic) | $0.15 | Earnings | source ↗ |
| Shares Outstanding | 128.0M | Entity | source ↗ |
| Cash from Operations | -$61.0M | Net | source ↗ |
| Cash from Financing | $64,000 | Net | source ↗ |
| Cash from Investing | — | — | source ↗ |
Insider activity
Form 4 open-market activity, last 180 days
No open-market Form 4 transactions filed in the last 180 days.
Restatement history
Point-in-timeNo material restatements detected across 241 annual fact-keys: this company's as-filed numbers have held between filings. Point-in-time and as-of history are available via the API.
Deeper fundamentals
A free API key reaches APLS’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.
Programmatic access
Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.
- These fundamentals, as filed
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/APLS
MCP tool:
get_sec_fundamentals ticker=APLS - The same figures as they were known on any past date
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/APLS/as-of/YYYY-MM-DD
MCP tool:
get_asof_fundamentals ticker=APLS as_of=YYYY-MM-DD - Fiscal-year trajectory: revenue, margins, free cash flow
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/APLS/history
MCP tool:
get_fundamentals_history ticker=APLS - Leverage, liquidity, margin and return ratios
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/financial-health/APLS
MCP tool:
get_financial_health ticker=APLS
Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.